|
|
Volumn 13, Issue 8, 2014, Pages 573-
|
|
Anticancer drugs: Horizons broaden for PI3Kδ inhibitors
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
P110DELTA INHIBITOR;
PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;
PI 3065;
UNCLASSIFIED DRUG;
ADOPTIVE TRANSFER;
BONE MARROW CELL;
BREAST CANCER;
CANCER CELL;
CANCER CELL LINE;
CANCER GROWTH;
CANCER INHIBITION;
CANCER RECURRENCE;
CANCER SURGERY;
CANCER SURVIVAL;
CD4+ T LYMPHOCYTE;
CD8+ T LYMPHOCYTE;
DISEASE RESISTANCE;
GENE SILENCING;
IMMUNE RESPONSE;
IMMUNOLOGICAL MEMORY;
IMMUNOREGULATION;
LUNG CANCER;
LYMPHOCYTE PROLIFERATION;
MELANOMA;
METASTASIS;
MYELOID DERIVED SUPPRESSOR CELL;
NONHUMAN;
NOTE;
PANCREAS ADENOCARCINOMA;
PRIORITY JOURNAL;
REGULATORY T LYMPHOCYTE;
SUPPRESSOR CELL;
T CELL DEPLETION;
THYMOMA;
TUMOR GROWTH;
ANIMALS;
ENZYME INHIBITORS;
IMMUNE TOLERANCE;
NEOPLASMS;
PHOSPHATIDYLINOSITOL 3-KINASES;
T-LYMPHOCYTES, REGULATORY;
|
|
EID: 84905382980
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4399 Document Type: Note |
|
Times cited : (2)
|
|
References (1)
|
